Business
RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting
Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of ChemotherapyMOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-deli
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KH8PPWGWgkhj4V41vXuuLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of Chemotherapy","length":241,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.","length":573,"tagName":"p"},{"type":"text","content":"The abstract, entitled “The TIGeR-PaC Phase 3 III Clinical Trial Examining Intra-Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub-Study,” explores RenovoRx’s lead product candidate, intra-arterial delivery of gemcitabine via RenovoCath (known as IAG), and its potential to reduce systemic levels of the chemotherapy gemcitabine and increase levels of its inactive metabolite compared with intravenous gemcitabine. Additionally, the abstract studies IAG administration and its direct correlation between the metabolite levels and CA 19-9, a biomarker commonly used to assess potential chemotherapy response.","length":650,"tagName":"p"},{"type":"text","content":"“This study provides important insights into how targeted intra-arterial delivery of chemotherapy may optimize drug distribution and pharmacologic activity in locally advanced pancreatic cancer,” said Dr. Ramtin Agah, RenovoRx’s Exe...